Cognition Therapeutics Files 8-K on Security Holder Votes
Ticker: CGTX · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: CTXI
TL;DR
CTXI filed an 8-K for security holder votes - details to follow.
AI Summary
Cognition Therapeutics, Inc. filed an 8-K on June 7, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as an official notification of these events.
Why It Matters
This filing indicates that Cognition Therapeutics held a vote among its security holders, a standard corporate governance procedure that can impact company direction or shareholder rights.
Risk Assessment
Risk Level: low — The filing is a procedural notification of a shareholder vote without immediate financial or operational implications disclosed.
Key Players & Entities
- Cognition Therapeutics, Inc. (company) — Registrant
- June 7, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted for a vote to Cognition Therapeutics' security holders?
The filing does not specify the exact matters voted upon, only that matters were submitted for a vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 7, 2024.
What is the primary standard industrial classification code for Cognition Therapeutics, Inc.?
The primary SIC code is 2836, for Biological Products (No Diagnostic Substances).
Where is Cognition Therapeutics, Inc.'s principal executive office located?
The principal executive offices are located at 2500 Westchester Avenue, Purchase, NY 10577.
What is the SEC file number for Cognition Therapeutics, Inc.?
The SEC file number is 001-40886.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-07 16:06:13
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CGTX The Nasdaq Stock Mar
Filing Documents
- tm2416762d1_8k.htm (8-K) — 30KB
- 0001104659-24-069635.txt ( ) — 199KB
- cgtx-20240607.xsd (EX-101.SCH) — 3KB
- cgtx-20240607_lab.xml (EX-101.LAB) — 33KB
- cgtx-20240607_pre.xml (EX-101.PRE) — 22KB
- tm2416762d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 7, 2024, Cognition Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Company's definitive proxy statement for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on April 26, 2024 . Proposal 1 – Election of Class III Directors. Each of Jack Khattar and Brett Monia, Ph.D. were elected to the Board of Directors as Class III directors to serve until the Company's 2027 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal as follows: Name For Withheld Broker Non-Votes Jack A. Khattar 13,573,718 2,573,793 8,421,943 Brett P. Monia, Ph.D. 15,650,742 496,769 8,421,943 Proposal 2 – Ratification of Independent Registered Public Accountants. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the 2024 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 23,994,293 301,998 273,163 0
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: June 7, 2024 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer